Researchers may have stumbled upon the secret to anti-aging medication in a pill that's already widely used and readily ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

VIP36, a new CB1 agonist, targets a cryptic pocket to provide analgesia for chronic pain while minimizing side effects and ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

In a study published in 2023, young and old Caenorhabditis elegans worms treated with the drug – which is normally used to ...

Scientists from the University of Liverpool have found that rilmenidine, a drug commonly used to treat high blood pressure, ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...